Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Non-Hodgkin lymphoma (NHL): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Non-Hodgkin lymphoma: the short answer

The US FDA has approved eight medicines on this page for non-Hodgkin lymphoma, each for specific patients. Eight of them are on at least one Gulf register we checked, so ask your hospital about local supply first. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Yescarta, Breyanzi, Kymriah, Columvi, Epkinly, Lunsumio, Brukinsa and Tecartus.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Local supply where listed; otherwise a named-patient import request filed by the treating hospital; cell and gene therapies at a qualified center.
Price: Quote on request.

What is non-Hodgkin lymphoma?

Lymphoma is a cancer of the lymph system, part of the immune system. Non-Hodgkin lymphomas begin when a B cell or T cell becomes abnormal and keeps dividing. The abnormal cells can spread to almost any part of the body. There are many types, including diffuse large B-cell, follicular and mantle cell lymphoma.^[1]

Symptoms can include swollen, painless lymph nodes in the neck, armpits or groin, unexplained weight loss, fever, soaking night sweats, cough or chest pain, ongoing weakness, and pain or fullness in the abdomen. A weakened immune system and certain infections raise the risk.^[1]

Diagnosis needs a biopsy. Treatment includes chemotherapy, radiation, targeted and biologic therapy, and sometimes watchful waiting. For relapsed or refractory lymphoma, US options include CAR-T cell therapies and bispecific antibodies, each approved for specific lymphoma types and prior treatments.^{[1, 2, 3]}

Non-Hodgkin lymphoma in the Gulf

We did not find published data on non-Hodgkin lymphoma from the Gulf countries that we could verify on 17 October 2026. The register status for each medicine below shows what we could check.

US FDA-approved medicines for non-Hodgkin lymphoma

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Yescarta (axicabtagene ciloleucel)
FDA-approved for adults with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of it, or relapses after two or more lines of therapy. It is a CAR-T cell therapy given at a certified center.^[2]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Jordan, India
Breyanzi (lisocabtagene maraleucel)
FDA-approved for adults with large B-cell lymphoma in specific situations after earlier treatment, as listed in the label. It is a CAR-T cell therapy given at a certified center.^[6]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, India, Pakistan
Kymriah (tisagenlecleucel)
FDA-approved for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, and some other blood cancers listed in the label. It is a CAR-T cell therapy given at a certified center.^[7]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Egypt
Columvi (glofitamab)
FDA-approved for adults with relapsed or refractory diffuse large B-cell lymphoma, or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy. It is a bispecific antibody given by intravenous infusion.^[8]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Egypt, Lebanon, Turkey, India, Pakistan
Epkinly (epcoritamab-bysp)
FDA-approved for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy, and some patients with follicular lymphoma as listed in the label. It is a bispecific antibody given by injection under the skin.^[3]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India, Pakistan
Lunsumio (mosunetuzumab)
FDA-approved for adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. It is a bispecific antibody given by intravenous infusion.^[9]
Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Qatar, Jordan, Turkey
Brukinsa (zanubrutinib)
FDA-approved for adults with mantle cell lymphoma after at least one prior therapy, relapsed or refractory marginal zone and follicular lymphoma, and chronic lymphocytic leukemia or small lymphocytic lymphoma, as listed in the label. It is taken by mouth.^[10]
Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, India
Tecartus (brexucabtagene autoleucel)
FDA-approved for adults with relapsed or refractory mantle cell lymphoma, and some adults with B-cell acute lymphoblastic leukemia. It is a CAR-T cell therapy given at a certified center.^[11]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[4, 5]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Turkey

How families in the Gulf can access these medicines

If the medicine is listed in your country. Ask your specialist and the hospital pharmacy about local supply first. A listing does not mean every hospital stocks the medicine, and another brand of the same medicine may also be registered, but local supply is usually the fastest route and you may not need us.

If it is not registered. The usual legal route is a named-patient request: the treating hospital, on your specialist's written request, asks the national regulator for permission to import the medicine for one patient, using the US FDA approval as the reference. In Saudi Arabia the SFDA Special Access Program guidance covers these requests; in Bahrain, NHRA Circular 41 of 2020 sets the procedure. Other Gulf countries have their own procedures, which the hospital pharmacy confirms.^{[12, 13]} Once approval is in place, Reserve Meds arranges supply through a US-licensed pharmaceutical wholesale partner to the hospital pharmacy.

For Yescarta, Breyanzi, Kymriah and Tecartus. These treatments are made for each patient or need a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for non-Hodgkin lymphoma

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for non-Hodgkin lymphoma?

Yes. The medicines on this page have US FDA approval for specific groups of patients: Yescarta, Breyanzi, Kymriah, Columvi, Epkinly, Lunsumio, Brukinsa and Tecartus. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Yescarta available in Saudi Arabia or the UAE?

Saudi Arabia: listed in the SFDA drugs list. Abu Dhabi: has an active code in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Yescarta?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Why does the exact lymphoma type matter?

Each US approval is for specific types, such as large B-cell, follicular or mantle cell lymphoma, and often after a set number of earlier treatments. The pathology report decides which options apply.

Do I always need treatment right away?

Not always. MedlinePlus notes that people without symptoms may not need treatment right away, which is called watchful waiting. Your hematologist decides.

Sources for the last two answers: ^{[8, 9]} ^[1]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

This page is general health information, not medical advice. It does not replace a consultation with your doctor.